UK Markets closed

Idorsia Ltd (0RQE.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
21.16-5.11 (-19.46%)
At close: 06:02PM BST
Full screen
Previous close26.27
Open26.56
Bid0.00 x 0
Ask0.00 x 0
Day's range26.18 - 26.84
52-week range26.18 - 26.84
Volume7,660
Avg. volumeN/A
Market cap2.778B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.14
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Phase 2a study results in binge eating disorder

    Allschwil, Switzerland – May 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that ACT-539313, a selective orexin-1 receptor antagonist, did not show an improvement over placebo in reducing the number of binge eating days per week in adult patients with moderate to severe binge eating disorder – the primary endpoint was therefore not met. ACT-539313 was very well tolerated over the treatment period of 12 weeks. Alberto Gimona, Head of Global Clinical Development of Idorsia, commented:“Assessing

  • Globe Newswire

    Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

    QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningComprehensive nighttime efficacy and unique daytime functioning data, together with a favorable safety profile, are included in the QUVIVIQ product labelThis approval makes QUVIVIQ, Europe's first dual orexin receptor antagonist, a new targeted mechanism of action that decreases overactive wakefulness in insomnia Allsch

  • Globe Newswire

    Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

    In the US, QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance1QUVIVIQ becomes Idorsia’s first commercial product in the United States, now available to help American adults who suffer from insomnia Allschwil, Switzerland & Radnor, PA, US – May 2, 2022Idorsia Ltd (SIX: IDIA) & Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25